Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6092)
All Articles published online
|
Publishing Process of This Article
|
Dec 21, 2013 (publication date) through Nov 9, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ishikawa T. Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2013; 19(47): 8861-8866 [PMID: 24379608 DOI: 10.3748/wjg.v19.i47.8861] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v19/i47/8861.htm |
| Number | Citing Articles |
| 1 |
Zhao-Shan Niu, Xiao-Jun Niu, Mei Wang. Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival. World Journal of Hepatology 2015; 7(1): 7-27 doi: 10.4254/wjh.v7.i1.7
|
| 2 |
Xiang-Qian Gu, Wei-Ping Zheng, Da-Hong Teng, Ji-San Sun, Hong Zheng. Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients. World Journal of Gastroenterology 2016; 22(9): 2749-2759 doi: 10.3748/wjg.v22.i9.2749
|
| 3 |
Guangcong Zhang, Xiangnan Yu, Peng Liu, Xiaoxi Huang, Xuemei Jiang. Efficacy of Nucleoside Analogs for Chronic Hepatitis B Virus-Related Hepatocellular Carcinoma After Curative Treatment: A Meta-Analysis. Digestive Diseases and Sciences 2018; 63(12): 3207 doi: 10.1007/s10620-018-5252-8
|
| 4 |
Shaozhen Rui, Jun Yan, Hui Zhang, Zhengfeng Wang, Wence Zhou. Intermediate-stage hepatocellular carcinoma patients with a high HBV-DNA load may benefit from postoperative anti-hepatitis B virus therapy. Medicine 2017; 96(30): e7608 doi: 10.1097/MD.0000000000007608
|
| 5 |
Er-lei Zhang, Zun-yi Zhang, Shu-ping Wang, Zhen-yu Xiao, Jin Gu, Min Xiong, Xiao-ping Chen, Zhi-yong Huang. Predicting the severity of liver cirrhosis through clinical parameters. Journal of Surgical Research 2016; 204(2): 274 doi: 10.1016/j.jss.2016.04.036
|
| 6 |
Y J Chang, K P Chung, Y J Chang, L J Chen. Long-term survival of patients undergoing liver resection for very large hepatocellular carcinomas. Journal of British Surgery 2016; 103(11): 1513 doi: 10.1002/bjs.10196
|
| 7 |
CHAOHUI ZUO, MAN XIA, QUNFENG WU, HAIZHEN ZHU, JINGSHI LIU, CHEN LIU. Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review). Oncology Letters 2015; 9(2): 527 doi: 10.3892/ol.2014.2727
|
| 8 |
Kazunori Kawaguchi, Masao Honda, Hajime Ohta, Takeshi Terashima, Tetsuro Shimakami, Kuniaki Arai, Taro Yamashita, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Takuya Komura, Masashi Unoura, Shuichi Kaneko. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B. Journal of Gastroenterology 2018; 53(6): 740 doi: 10.1007/s00535-017-1386-2
|
| 9 |
Zhenya Gao, Huanxia Jia, Fang Yu, Hongfang Guo, Baoyu Li. KIF2C promotes the proliferation of hepatocellular carcinoma cells in vitro and in vivo. Experimental and Therapeutic Medicine 2021; 22(4) doi: 10.3892/etm.2021.10528
|
| 10 |
Jiansong Wu, Zhiwei Yin, Liuxia Cao, Xiaodan Xu, Tao Yan, Changting Liu, Diangeng Li. Adjuvant pegylated interferon therapy improves the survival outcomes in patients with hepatitis-related hepatocellular carcinoma after curative treatment. Medicine 2018; 97(28): e11295 doi: 10.1097/MD.0000000000011295
|
| 11 |
Yafei Zhang, Wei Li, Zhongping Liu, Jun Ye, Guizhou Zou, Zhenhua Zhang, Jiabin Li. Combination therapy based on pegylated interferon alfa improves the therapeutic response of patients with chronic hepatitis B who exhibit high levels of hepatitis B e-antigen at 24 weeks. Medicine 2019; 98(36): e17022 doi: 10.1097/MD.0000000000017022
|
| 12 |
Chern-Horng Lee, Chien-Heng Shen, Cho-Li Yen, Tzung-Hai Yen, Sen-Yung Hsieh. Discontinuing Hepatitis Activity Reduced Hepatocellular Carcinoma Recurrence after Primary Curative Therapy. Journal of Personalized Medicine 2023; 13(3): 397 doi: 10.3390/jpm13030397
|
| 13 |
Yong Keun Park, Sung Kyu Song, Bong-Wan Kim, Seung-Keun Park, Chul-Woon Chung, Hee-Jung Wang. Prognostic significance of microvascular invasion in tumor stage for hepatocellular carcinoma. World Journal of Surgical Oncology 2017; 15(1) doi: 10.1186/s12957-017-1292-3
|
| 14 |
Yun Wang, Xiaogang Xiang, Liwen Chen, Zhujun Cao, Rebecca Bao, Huijuan Zhou, Weiliang Tang, Jie Lu, Lanyi Lin, Qing Xie, Shisan Bao, Hui Wang. Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patientsviareducing severity and progression of malignancy. Oncotarget 2016; 7(36): 58553 doi: 10.18632/oncotarget.10155
|
| 15 |
Rodolfo Sacco, Michela Antonucci, Giampaolo Bresci, Ambra Corti, Luca Giacomelli, Valeria Mismas, Maurizio Rainieri, Antonio Romano, Roberto Eggenhoffner, Emanuele Tumino, Giuseppe Cabibbo. Curative therapies for hepatocellular carcinoma: an update and perspectives. Expert Review of Anticancer Therapy 2016; 16(2): 169 doi: 10.1586/14737140.2016.1123625
|
| 16 |
Chia‐Jui Yen, Yu‐Lin Ai, Hung‐Wen Tsai, Shih‐Huang Chan, Chia‐Sheng Yen, Kuang‐Hsiung Cheng, Yun‐Ping Lee, Chia‐Wei Kao, Yu‐Chun Wang, Yi‐Lin Chen, Cheng‐Han Lin, Tsunglin Liu, Huey‐Pin Tsai, Jen‐Ren Wang, Ih‐Jen Su, Wenya Huang. Hepatitis B virus surface gene pre‐S2 mutant as a high‐risk serum marker for hepatoma recurrence after curative hepatic resection. Hepatology 2018; 68(3): 815 doi: 10.1002/hep.29790
|